nach oben

PharmacoEconomics

Erschienen in:

01.10.2016 | Commentary

Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?

verfasst von: Livio Garattini, Alessandro Curto

Erschienen in: PharmacoEconomics | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Excerpt

Performance-based agreements (PbAs) refer to pricing and reimbursement agreements based on patient outcomes [1]. Different from financial-based agreements (FbAs), consisting of price/dose discounts, the underlying philosophy of PbAs is to pay only for patients responding to therapy, a very challenging issue from a clinical perspective, while appealing from a political viewpoint [2]. …

Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.CrossRefPubMedPubMedCentral

Garattini L, Curto A, van de Vooren K. Italian risk-sharing agreements on drugs: are they worthwhile? Eur J Health Econ. 2015;16(1):1–6.CrossRefPubMed

Towse A, Garrison LP. Can’t get no satisfaction? Will pay for performance help? Pharmacoeconomics. 2010;28:93–102.CrossRefPubMed

Navarria A, Drago V, Gozzo L, Longo L, Mansueto S, Pignataro G, Drago F. Do the current performance-based schemes in Italy really work? “Success Fee”: a novel measure for cost-containment of drug expenditure. Value Health. 2014. (Epub ahead of print).

van de Vooren K, Curto A, Freemantle N, Garattini L. Market-access agreements for anti-cancer drugs. J R Soc Med. 2015;108(5):166–70.CrossRefPubMed

http://www.agenziafarmaco.gov.it/it/content/lista-aggiornata-dei-registri-e-dei-piani-terapeutici-web-based.

AIFA. L’uso dei farmaci in Italia. Rapporto nazionale anno 2014. Osservatorio Nazionale sull’impiego dei Medicinali, OsMed. Roma, 2015. AIFA.

Parkinson B, Elshaug A. Authors’ reply to Palozzo and Messori: ‘‘Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review’’. Pharmacoeconomics. 2016;34(4):421–42.CrossRefPubMed

Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ. 2010;340:c1672.CrossRefPubMed

10.

Montilla S, Xoxi E, Russo P, Cicchetti A, Pani L. Monitoring registries at italian medicines agency: fostering access, guaranteeing sustainability. Int J Technol Assess Health Care. 2015;31(4):210–3.CrossRefPubMed

11.

Scherer FM. The pharmaceutical industry. Prices and progress. N Engl J Med. 2004;351:927–32.CrossRefPubMed

12.

Garattini L, Padula A. ‘Appropriateness’ in Italy: a ‘Magic Word’ in pharmaceuticals? Appl Health Econ Health Policy. 2016 (Epub ahead of print).

Titel: Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?
verfasst von: Livio Garattini
Alessandro Curto
Publikationsdatum: 01.10.2016
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 10/2016
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-016-0420-1

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2016

EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes

Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence

Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3

Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer

A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy

Sustainable Financing of Innovative Therapies: A Review of Approaches